First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

European Journal of Haematology

Volumn 79, Issue 3, 2007, Pages 240-243

  Schmidmaier, Ralf ^a   Baumann, Philipp ^a   Bumeder, Irmgard ^a   Meinhardt, Gerold ^a   Straka, Christian ^a   Emmerich, Bertold ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bendamustine; Bortezomib; Cell adhesion mediated drug resistance; Clinical trial; Multiple myeloma; Simvastatin

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; SIMVASTATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL ADHESION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BORONIC ACIDS; CELL ADHESION; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; SALVAGE THERAPY; SIMVASTATIN;

EID: 34547798983     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00902.x     Document Type: Article

References (10)

1. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004 104 : 1825 32.
2. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999 93 : 1658 67.
3. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002 16 : 1362 71.
4. van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003 102 : 3354 62.
5. Holmberg M, Sandberg C, Nygren P, Larsson R. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs 1994 5 : 598 600.
6. Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isgenic multiple myeloma cell line mode. Cancer Res 2003 63 : 7900 6.
7. Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 2006 17 : 621 9.
8. van der Spek E, Bloem AC, van de Donk NWCJ, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM. Dose-finding study of high dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006 91 : 542 5.
9. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996 2 : 483 91.
10. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999 84 : 413 28.